HighTide Therapeutics, Inc. (2511.HK), founded in 2011, is an innovative biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across CKM diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
Qualifications & Academic Honors
- National High-Tech Enterprise of China
- Innovative Small and Medium-sized Enterprise (SME)
- First batch of Strategic Enterprise Partners of the Hong Kong SAR Government
- Research findings presented at top-tier academic conferences, including American Society of Nephrology (ASN), European Renal Association (ERA), Global Cardiovascular Clinical Trialists Forum (CVCT), European Society of Cardiology (ESC), American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Diabetes Association (ADA), and European Association for the Study of Diabetes (EASD)
- Research findings published in prestigious journals such as Nature, JAMA, and NEJM